Abbott's Third-Quarter Sales Rose 14.5%, But Reported Earnings Per Share Fell To $0.53 From $0.94

Adjusted earnings rose to $1.42 a share as Exact Sciences lifted sales, while amortization, interest and settlements cut reported profit.

Share
Abbott's Third-Quarter Sales Rose 14.5%, But Reported Earnings Per Share Fell To $0.53 From $0.94

Abbott's third-quarter sales rose 14.5% to $13,013 million, but earnings under standard accounting fell to $0.53 a share from $0.94 a year earlier, according to an 8-K and news release filed Wednesday. Adjusted earnings went the other way, rising to $1.42 from $1.30, and the gap between the two is the story.

The finding: sales up, reported profit down

On a comparable basis, which counts Exact Sciences in both years and strips out currency, sales grew 7.0%. Abbott bought Exact Sciences, a cancer diagnostics company, on March 23, 2026, so the reported 14.5% includes a business that was not in the prior-year quarter.

Net earnings were $920 million versus $1,644 million a year earlier, down 44.1%. Operating earnings fell 34.0% to $1,358 million from $2,057 million.

Cancer Diagnostics, the former Exact Sciences business, brought in $968 million of sales and grew 13.8% comparably, led by Cologuard. Medical Devices grew 7.8% comparably, with double-digit growth in Electrophysiology and Rhythm Management. Nutrition grew 4.9% comparably and Established Pharmaceuticals 8.4%.

Chairman and CEO Robert B. Ford said Abbott "delivered strong third-quarter results, reflecting balanced growth across our portfolio."

The catch: what sits between $0.53 and $1.42

Abbott's adjusted figure excludes $1.557 billion of after-tax charges, or $0.89 a share. Amortization of intangible assets was $841 million, double the $420 million of a year earlier.

The specified items also include legal settlements of about $670 million, tied to the Gill case and necrotizing enterocolitis (NEC) claims for roughly 2,000 additional infants. Other net expenses of $178 million cover acquisitions, restructuring and other items.

Below the operating line, net interest expense was $297 million versus $44 million. Selling, general and administrative costs rose 39.8% to $4,266 million, against 14.5% sales growth.

For the first nine months, reported earnings were $1.67 a share versus $2.70, while adjusted earnings were $3.88 versus $3.65.

Guidance and what comes next

Abbott expects full-year comparable sales growth of about 6.0%. It tightened its 2026 adjusted earnings range to $5.50 to $5.55 a share, reaffirming the midpoint of the prior range. For the fourth quarter it guided to $1.62 to $1.67 adjusted. It gave no standard-accounting forecast, saying it cannot predict items such as restructuring, acquisition costs and currency.

The company declared a quarterly dividend of $0.63 a share, payable Nov. 16 to holders of record on Oct. 15. Yahoo Finance reports a U.S. launch of Libre Duo 10 Day is planned later in 2026.

The fourth-quarter adjusted range of $1.62 to $1.67 a share is the next number Abbott has put its name to.

Sources

More on Abbott Laboratories

All Abbott Laboratories (ABT) coverage →